Volume 164, Issue 6, Pages (December 2000)

Slides:

Advertisements

Similar presentations

European Urology Focus

Advertisements

Volume 57, Issue 3, Pages (March 2010)

Volume 188, Issue 4, Pages (October 2012)

Volume 187, Issue 6, Pages (June 2012)

Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire

Volume 55, Issue 1, Pages 1-8 (January 2009)

Volume 180, Issue 3, Pages (September 2008)

Volume 164, Issue 6, Pages (December 2000)

Volume 155, Issue 3, Pages (March 1996)

MP60-03 PROSTATE CANCER IN THE ELDERLY

Volume 41, Issue 6, Pages (June 2002)

Volume 70, Issue 3, Pages (September 2016)

Volume 195, Issue 4, Pages e13-e14 (April 2016)

Volume 45, Issue 5, Pages (May 2004)

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 6, Pages (December 2015)

Volume 195, Issue 5, Pages (May 2016)

Volume 50, Issue 1, Pages (July 2006)

Effect of antibacterials on biofilms

Volume 62, Issue 5, Pages (November 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

2327 PROSTATE CANCER STAGE, GRADE AND POSITIVE MARGIN RATE IN MEN WITH PSA ≥ 1 ng/ml UNDERGOING RADICAL PROSTATECTOMY: POPULATION DATA ANALYSIS Sergey.

European Urology Focus

The Male Factor in Fertility and Infertility. II

Volume 53, Issue 4, Pages (April 2008)

Volume 61, Issue 5, Pages (May 2012)

Volume 61, Issue 5, Pages (May 2012)

Volume 68, Issue 5, Pages (November 2015)

Volume 199, Issue 4, Pages e143-e144 (April 2018)

Volume 189, Issue 1, Pages S26-S33 (January 2013)

Volume 191, Issue 1, Pages (January 2014)

Seminal Vesicle Invasion by Adenocarcinoma of the Prostate

Volume 52, Issue 3, Pages (September 2007)

Volume 183, Issue 3, Pages (March 2010)

Volume 189, Issue 1, Pages (January 2013)

Pseudohyperplastic Adenocarcinoma of the Prostate

Towards Early and More Specific Diagnosis of Prostate Cancer

Prostate Cancer Detection: A View of the Future

Volume 54, Issue 5, Pages (November 2008)

Counselling the Prostate Cancer Patient

Luis Martínez-Piñeiro European Urology Supplements

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study Alexander I. Hinev, Vesselin I. Hadjiev,

Volume 54, Issue 3, Pages (September 2008)

Volume 65, Issue 6, Pages (June 2014)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

Volume 50, Issue 5, Pages (November 2006)

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

This Month in AJKD American Journal of Kidney Diseases

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 65, Issue 6, Pages (June 2014)

Volume 74, Issue 6, Pages (December 2018)

Volume 54, Issue 5, Pages (November 2008)

Minutes of the Board of Directors Meeting

The Reply The American Journal of Medicine

Assessing fitness for surgery: a comparison of questionnaire, incremental shuttle walk, and cardiopulmonary exercise testing in general surgical patients†

Society for Investigative Dermatology 2010 Meeting Minutes

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Research Snippets Journal of Investigative Dermatology

Reviewer Acknowledgment

The failure of breast cancer screening

Tai Ji: The law of inflammatory response

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 76, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 164, Issue 6, Pages 1956-1960 (December 2000) USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND α1- PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER PATRIK FINNE, WAN-MING ZHANG, ANSSI AUVINEN, JARI LEINONEN, LIISA MÄÄTTÄNEN, SAKARI RANNIKKO, TEUVO L.J. TAMMELA, ULF-HÅKAN STENMAN The Journal of Urology Volume 164, Issue 6, Pages 1956-1960 (December 2000) DOI: 10.1016/S0022-5347(05)66927-3 Copyright © 2000 American Urological Association, Inc. Terms and Conditions

Fig. 1 Correlation between uncorrected PSA-α1-protease inhibitor (API) and nonspecific background in 42 female sera without PSA immunoreactivity. PSA-α1-protease inhibitor and nonspecific background were determined in separate wells (y = −0.0003 + 0.9485 x, r = 0.91). The Journal of Urology 2000 164, 1956-1960DOI: (10.1016/S0022-5347(05)66927-3) Copyright © 2000 American Urological Association, Inc. Terms and Conditions

Fig. 2 Proportion of PSA-α1-protease inhibitor (API) plotted against proportion of free PSA in sera with total PSA 4 to 10 μg./l. from 44 prostate cancer cases and 210 controls. There was no correlation between proportions of PSA-α1-protease inhibitor and free PSA (r = 0.03, p = 0.56). The Journal of Urology 2000 164, 1956-1960DOI: (10.1016/S0022-5347(05)66927-3) Copyright © 2000 American Urological Association, Inc. Terms and Conditions

Fig. 3 ROC curves of total PSA, proportions of free PSA and PSA-α1-protease inhibitor (API), and probability of prostate cancer obtained by logistic regression analysis of logarithm of PSA-α1-protease inhibitor and proportion of free PSA in serum with PSA 4 to 10 μg./l. AUC, area under ROC curve. The Journal of Urology 2000 164, 1956-1960DOI: (10.1016/S0022-5347(05)66927-3) Copyright © 2000 American Urological Association, Inc. Terms and Conditions